Our research is aimed at elucidating the mechanism of adult T-cell leukemia/lymphoma development at the molecular and individual levels and developing new preventive and therapeutic methods.
Our mission is to elucidate the pathogenesis of HAM/TSP, an inflammatory neurological disease in the spinal cord caused by HTLV-1 infection, and to develop new therapeutic strategies.
The mission of our team is to develop the new antivirals by the artificial noninfectious virus, replicon, assay system. The research for HCV, HBV, Flu, and human coronaviruses including SARS-CoV-2, is within our scope.
The mission of our research group is to develop new therapeutics against certain refractory viral infections such as HIV and HBV. We also aim to establish novel strategies to combat with emerging diseases including COVID-19.
Our mission is to put new medical seeds born from the results of basic research in various fields into practical use as pharmaceuticals and medical technology. It aims at a smooth transition from the basic research stage to clinical application by continuously capturing non-clinical research to clinical development.